BioCentury
ARTICLE | Clinical News

ATI-1123: Phase I started

February 1, 2010 8:00 AM UTC

Azaya began an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous ATI-1123 starting at 15 mg/m 2 in about 24 patients. ...